Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Coronavirus puts Big Pharma’s IP regime to the test
Coronavirus crisis may bring out old tool in disease fights: suspension of drug patents
Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism
In rare move, Gilead gives up ‘orphan’ status for experimental coronavirus drug
Ford School hosts conversation on drug patent system reform
Why are Drug Prices So High? Investigating the outdated US patent system
Ten years ago, I testified before Congress about drug pricing — and it’s only gotten worse. Here’s what’s wrong, and how we may be able to fix it.
After a pharma lobbying blitz, Congress softens legislation on drug patents
The Health 202: The Supreme Court banned patenting genes. But Congress might change that.
Cornyn to launch bill against ‘patent thickets’